Shareef Mansour
Advanced Heart Failure and Transplant Cardiology · Galveston, TXNPI 1063068732
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Abiomed at 33.2% of the total. 2025 is the largest year on record at $2,131, more than ten times the $29 reported in 2022. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in TX, where the typical reported total is $11,093.
Across 38 payments — averaging $114.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- Abbott$1K
- Alnylam Pharmaceuticals Inc.$932
- Bayer$200
- Edwards Lifesciences$153
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$127
- plus $347 from 7 others
What the payments were for
- Consulting fees$1,09325%
- Travel & lodging$1,10926%
- Food & beverage$2,03647%
- Education$972%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 13 | $1,441 |
| Abbott | 8 | $1,135 |
| Alnylam Pharmaceuticals Inc. | 2 | $932 |
| Bayer | 1 | $200 |
| Edwards Lifesciences | 1 | $153 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $127 |
| Endotronix, Inc. | 1 | $119 |
| Novo Nordisk | 3 | $97 |
| Lexicon Pharmaceuticals, Inc. | 1 | $31 |
| Boston Scientific | 1 | $29 |
| Pfizer | 1 | $27 |
| Impulse Dynamics (USA) Inc. | 1 | $23 |
| Itamar Medical Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,335 in reported general payments places this provider in the 30th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 160 | $3,637,320 |
| VyndaqelTafamidis Meglumine | 59 | $1,194,870 |
| JardianceEmpagliflozin | 151 | $111,696 |
| EntrestoSacubitril/Valsartan | 58 | $49,407 |
| EliquisApixaban | 42 | $29,840 |
| Bumetanide | 11 | $1,909 |
| Metoprolol Succinate | 44 | $714 |
| Spironolactone | 113 | $354 |
| Torsemide | 20 | $284 |
| Amlodipine Besylate | 14 | $180 |
| Amiodarone Hcl | 12 | $166 |
| Atorvastatin Calcium | 24 | $110 |
| Carvedilol | 18 | $86 |
| Furosemide | 21 | $79 |
| Warfarin Sodium | 13 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $27 | $4,862,029261 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Galveston
- Wissam KhalifeGalveston$17K
- Khaled ChatilaGalveston$7K
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Allen AndersonSan Antonio$413K
- Martin BerkDallas$379K
- Aasim AfzalPlano$336K
- Kunjan BhattAustin$324K
- Barry TrachtenbergHouston$306K
- Shelley HallDallas$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.